Drug intelligence / Profile preview

RV16UB

Development stage: Phase 1
Lead developer: Merck
Administration: Intranasal

Overview

RV16UB is a standardized preparation of human rhinovirus 16 (HRV-16) developed by the U-BIOPRED (Unbiased Biomarkers for the Prediction of Respiratory Disease Outcomes) consortium. It is utilized as a clinical challenge agent to induce controlled upper respiratory tract infections and asthma exacerbations in research settings. By administering RV16UB intranasally, researchers can study the longitudinal biomarker profiles and "handprints" (high-dimensionality phenotypes) of asthma in both healthy volunteers and asthmatic patients. This allows for the evaluation of safety, tolerability, and the underlying biological mechanisms of viral-induced respiratory distress.

Other names: human rhinovirus 16HRV-16HRV16HRV 16U-BIOPRED human rhinovirus 16

Targets

ICAM1 (Intercellular Adhesion Molecule 1)

Beyond the preview

Go deeper on RV16UB.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RV16UB.

Explore the full profile